Where is the advantage of Chen Wei's team vaccine? Expert: Large-scale rapid vaccination can be achieved

What are the advantages of Chen Wei's team's single-dose vaccine?

Expert: Means that large-scale and rapid population vaccination can be achieved

　　[Global Times reporter Zhao Juehui, Bai Yunyi, and Hu Yuwei] The adenovirus vector vaccine Ad5-nCoV, jointly developed by the team of Academician Chen Wei of the Academy of Military Sciences and Cansino Bio, announced the interim analysis results of the Phase III clinical trial in Pakistan on the 8th.

Several experts in related fields told the Global Times reporter that the most prominent feature of the vaccine is a single injection, while other common vaccines usually require two injections.

This means that large-scale and rapid population vaccination can be achieved, which is of great significance to the overall epidemic prevention strategy of society.

　　Pakistan’s special assistant to the prime minister for national health affairs, Feisou Sudan, said on the 8th that the interim analysis of the Phase III clinical trial of Ad5-nCoV in the country showed that 28 days after a single injection of the vaccine, the vaccine’s protective efficacy against severe new coronary pneumonia is 100%, the overall protective effect is 74.8%, and there is no serious adverse reaction related to the vaccine.

　　According to reports, Cansino vaccine is an adenovirus vector vaccine. The Oxford/AstraZeneca vaccine, Johnson & Johnson vaccine and Russia's "Satellite V" also use the same technical route.

Among them, only Cansino vaccine and Johnson & Johnson vaccine are single-dose vaccines.

On January 29 this year, Johnson & Johnson announced that the results of the Phase III clinical trial of its vaccine showed that 28 days after a single dose of the new crown vaccine, the total effective rate against moderate and severe new coronary pneumonia reached 66%, preventing serious diseases in all research areas The effective rate is 85%.

In contrast, although the Johnson & Johnson vaccine is also a single shot, its effective rate of 66% is not mild, and 85% is less effective than Ad5-nCoV in preventing severe illness.

　　A Chinese expert in immunology told the Global Times reporter that Ad5-nCoV's effective rate data is very good, especially considering that it is one of the few single-dose new crown vaccines. In the absence of a second dose of booster effect, It is difficult to reach high levels of neutralizing antibody titers.

"If you have to make a horizontal comparison, the effectiveness of Ad5-nCoV should be compared with the data after the first shot of other vaccines." Vaccine professionals Zhuang Shili and doctor also told the Global Times reporter, although on the surface, The overall effectiveness of the vaccine seems to be lower than that of several other adenovirus vector vaccines, but an important prerequisite must be taken into consideration, that is, Cansino vaccine is one of the rare single-dose vaccines.

　　Zhuang Shilihe believes, “Among adenovirus vector vaccines, the data of AstraZeneca vaccine is rather confusing. Overall, the double-dose effective rate is only 70%; the data of the Russian'satellite V’ vaccine is relatively optimistic, and the overall double-dose effective rate is 91.6%, is the only adenovirus vector vaccine with an overall effective rate of more than 90%. According to a related paper published by The Lancet, the effective rate of'Satellite V'after the first injection is 73.1%. Overall, The CanSino vaccine has a single shot effective rate of 65.7%, which is a very good result."

　　An immunologist interviewed by a reporter from the "Global Times" analyzed that the procedure for single-dose vaccination is simple, and more people can be vaccinated within the same period of time, which is beneficial to protect as many people as possible in the shortest time.

Zhuang Shilihe also believes that Ad5-nCoV can achieve rapid mass vaccination of the population, and the high rate of critical illness prevention means that the pressure on hospital beds can be greatly reduced.

It is understood that another advantage of Cansino vaccine is that it only needs to be stored at 2 to 8 degrees Celsius, suitable for transportation and distribution.

　　However, the data released by Pakistan this time did not mention whether the effectiveness of Cansino vaccine will be affected by virus mutation.

Previously, Johnson & Johnson, AstraZeneca, etc. have reported that the vaccine's protective efficacy against South African mutant strains has been reduced.

In addition, an immunologist interviewed by the Global Times added that it is necessary to further observe the adverse reaction data of the Cansino vaccine, because the adenovirus vector vaccine is essentially similar to a cold virus and may cause some cold symptoms during the vaccination process. Whether it is recommended for people with weaker health to receive such vaccines needs further observation.